Department of Medicine, Center for Tobacco Control Research and Education and Division of General Internal Medicine, University of California, San Francisco, San Francisco, California, United States of America.
Department of Medicine, Division of Cardiology, University of California, San Francisco, San Francisco, California, United States of America.
PLoS One. 2023 Sep 13;18(9):e0289058. doi: 10.1371/journal.pone.0289058. eCollection 2023.
Little is known about whether people who use both tobacco and cannabis (co-use) are more or less likely to have mental health disorders than single substance users or non-users. We aimed to examine associations between use of tobacco and/or cannabis with anxiety and depression.
We analyzed data from the COVID-19 Citizen Science Study, a digital cohort study, collected via online surveys during 2020-2022 from a convenience sample of 53,843 US adults (≥ 18 years old) nationwide. Past 30-day use of tobacco and cannabis was self-reported at baseline and categorized into four exclusive patterns: tobacco-only use, cannabis-only use, co-use of both substances, and non-use. Anxiety and depression were repeatedly measured in monthly surveys. To account for multiple assessments of mental health outcomes within a participant, we used Generalized Estimating Equations to examine associations between the patterns of tobacco and cannabis use with each outcome.
In the total sample (mean age 51.0 years old, 67.9% female), 4.9% reported tobacco-only use, 6.9% cannabis-only use, 1.6% co-use, and 86.6% non-use. Proportions of reporting anxiety and depression were highest for the co-use group (26.5% and 28.3%, respectively) and lowest for the non-use group (10.6% and 11.2%, respectively). Compared to non-use, the adjusted odds of mental health disorders were highest for co-use (Anxiety: OR = 1.89, 95%CI = 1.64-2.18; Depression: OR = 1.77, 95%CI = 1.46-2.16), followed by cannabis-only use, and tobacco-only use. Compared to tobacco-only use, co-use (OR = 1.35, 95%CI = 1.08-1.69) and cannabis-only use (OR = 1.17, 95%CI = 1.00-1.37) were associated with higher adjusted odds for anxiety, but not for depression. Daily use (vs. non-daily use) of cigarettes, e-cigarettes, and cannabis were associated with higher adjusted odds for anxiety and depression.
Use of tobacco and/or cannabis, particularly co-use of both substances, were associated with poor mental health. Integrating mental health support with tobacco and cannabis cessation may address this co-morbidity.
目前尚不清楚同时使用烟草和大麻(共同使用)的人是否比单一物质使用者或非使用者更有可能出现心理健康障碍。我们旨在研究使用烟草和/或大麻与焦虑和抑郁之间的关联。
我们分析了 COVID-19 公民科学研究的数据,这是一项数字队列研究,于 2020 年至 2022 年期间通过在线调查,从全美范围内的便利样本中收集了 53843 名美国成年人(≥18 岁)的数据。过去 30 天的烟草和大麻使用情况在基线时进行了自我报告,并分为四种排他性模式:仅使用烟草、仅使用大麻、同时使用两种物质、不使用。焦虑和抑郁在每月的调查中反复测量。为了考虑参与者内精神健康结果的多次评估,我们使用广义估计方程来检查烟草和大麻使用模式与每种结果之间的关联。
在总样本中(平均年龄为 51.0 岁,67.9%为女性),4.9%报告仅使用烟草,6.9%报告仅使用大麻,1.6%报告同时使用两种物质,86.6%报告不使用。报告焦虑和抑郁的比例最高的是共同使用组(分别为 26.5%和 28.3%),最低的是非使用组(分别为 10.6%和 11.2%)。与不使用相比,心理健康障碍的调整后比值最高的是共同使用(焦虑:OR = 1.89,95%CI = 1.64-2.18;抑郁:OR = 1.77,95%CI = 1.46-2.16),其次是仅使用大麻,然后是仅使用烟草。与仅使用烟草相比,共同使用(OR = 1.35,95%CI = 1.08-1.69)和仅使用大麻(OR = 1.17,95%CI = 1.00-1.37)与焦虑的调整后比值更高相关,但与抑郁无关。香烟、电子烟和大麻的每日使用(与非每日使用相比)与焦虑和抑郁的调整后比值更高相关。
使用烟草和/或大麻,特别是同时使用两种物质,与不良心理健康有关。将心理健康支持与烟草和大麻戒除相结合可能可以解决这种共病问题。